China Sees First Attack On ‘Morning-After’ Pill Under ‘One-Child’ Policy
This article was originally published in PharmAsia News
The “morning-after” pill in China, almost a common drug at this point in a 30-year national “one-child” policy, has become controversial since a provincial capital required detailed identification of women buying the protection.
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
From enforced detention to hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.